Life Biosciences
At Life Biosciences, we are on a mission to reverse age-related diseases. Our platform, termed epigenetic restoration, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect. It has the potential to rejuvenate cells and restore function in many age-related diseases. We are the sole company with intellectual property covering the therapeutic use of our epigenetic restoration technology. We are also the only company to have received FDA approval to advance this technology into human clinical studies. While our initial clinical trial is for optic neuropathies, our science has the potential to bring tremendous benefit to patients suffering from multiple age-related diseases.www.lifebiosciences.com
12
MENTIONS
8
EPISODES
6
PODCASTS
Search complete. 12 mentions across 8 episodes found for "Life Biosciences".
Sep 9, 2026
Yaron BrookHOST
disease.
Yaron BrookHOST
Life Biosciences has begun the first human trial of ER100, a gene therapy designed to partially reset epigenetic programs in surviving retinal ganglion cells.
Yaron BrookHOST
The study targets open angle glaucoma and
Yaron BrookHOST
non-arteritic anterior ischematic optic neuropathy.
MarciaNARRATOR
FDA drug approval is divided into separate steps, and the job of the first phase, which will eventually encompass giving a single injection to 12 patients with glaucoma and last up to five years, is to show only that ER100 does no harm.
MarciaNARRATOR
But Sinclair and Life Biosciences, the company that licensed the therapy and is running the trial, is hoping for much more.
MarciaNARRATOR
A substance that can undo damage in the optic nerve by reversing its history might be able to reverse damage in any cell by returning it to its former state.
MarciaNARRATOR
And assuming cells could be prevented from ever growing old, humans could, at least theoretically, live forever.
17 MINS LATER
MarciaNARRATOR
Throughout the industry, I found that the early days of massive start-ups touting grand plans, had been replaced by more careful talk, and companies now primarily highlight the practical, near-term benefits of their work.
MarciaNARRATOR
The CEO of Altos Labs, Hale Barron, told me that Altos wanted medicine to move from a disease care model to a true health care model.
MarciaNARRATOR
And Jerry McLaughlin, the CEO of Life Biosciences, which licensed Sinclair's ER-100 treatment, emphasized the focus of their work was really on the quality of a life, not its length.
MarciaNARRATOR
But Sinclair remained unafraid to make the claims others danced around.
JeanNARRATOR
FDA drug approval is divided into separate steps, and the job of the first phase, which will eventually encompass giving a single injection to 12 patients with glaucoma and last up to five years, is to show only that ER-100 does no harm.
JeanNARRATOR
But Sinclair and Life Biosciences, the company that licensed the therapy, is running the trial, is hoping for much more.
JeanNARRATOR
The substance that can undo damage in the optic nerve by reversing its history might be able to reverse damage in any cell by returning it to its earlier state.
JeanNARRATOR
And assuming cells could be prevented from ever growing old, humans could, at least theoretically, live forever.
SasakiCORRESPONDENT
The key to this research is the so-called Yamanaka gene, which Professor Shinya Yamanaka of Kyoto University discovered in the study of creating iPS cells.
SasakiCORRESPONDENT
Life Biosciences, an American biotech company, has started a clinical trial of the treatment method called ER-100, which uses this technology.
SasakiCORRESPONDENT
The target is a patient with autonomic nervous system disorder due to internal injuries.
SasakiCORRESPONDENT
This year, the company announced that it has applied for the first patient in June.
JeanNARRATOR
FDA drug approval is divided into separate steps, and the job of the first phase, which will eventually encompass giving a single injection to 12 patients with glaucoma and last up to five years, is to show only that ER-100 does no harm.
JeanNARRATOR
But Sinclair and Life Biosciences, the company that licensed the therapy, is running the trial, is hoping for much more.
JeanNARRATOR
The substance that can undo damage in the optic nerve by reversing its history might be able to reverse damage in any cell by returning it to its earlier state.
JeanNARRATOR
And assuming cells could be prevented from ever growing old, humans could, at least theoretically, live forever.
Robert LufkinHOST
That mouse experiment just became a human one.
Robert LufkinHOST
In January twenty twenty-six, the FDA cleared Boston-based Life Biosciences, a company that David Sinclair co-founded, to run the first ever human trial of partial epigenetic reprogramming.
Robert LufkinHOST
And on June ninth, twenty twenty-six, the first patient was dosed.
Robert LufkinHOST
The therapy is called ER one hundred.
JeanHOST
FDA drug approval is divided into separate steps, and the job of the first phase, which will eventually encompass giving a single injection to twelve patients with glaucoma and last up to five years, is to show only that ER-one hundred does no harm.
JeanHOST
But Sinclair and Life Biosciences, the company that licensed the therapy, is running the trial, is hoping for much more.
JeanHOST
The substance that can undo damage in the optic nerve by reversing its history might be able to reverse damage in any cell by returning it to its earlier state.
JeanHOST
And assuming cells could be prevented from ever growing old, humans could, at least theoretically, live forever.
Julian IssaHOST
Hmm
Jamie JusticeGUEST
... is big news over the last year was Life Biosciences-
Julian IssaHOST
Yeah
Jamie JusticeGUEST
... that they used an AAV-based therapy to do epigenetic reprogramming.
13 MINS LATER
Julian IssaHOST
Two questions to follow up.
Jamie JusticeGUEST
Yeah.
Julian IssaHOST
The first one is, will B- Life Biosciences enter the XPRIZE?
Jamie JusticeGUEST
I can definitively at this time say no.